Citadel Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.73M	Buy	515,900 +446,600	+644%	+$5.64M	﹤0.01%	4120
2025 Q4	$1.15M	Buy	69,300 +30,900	+80%	+$441K	﹤0.01%	7085
2025 Q3	$452K	Sell	38,400 -162,600	-81%	-$1.68M	﹤0.01%	9385
2025 Q2	$1.93M	Buy	201,000 +158,900	+377%	+$879K	﹤0.01%	5771
2025 Q1	$264K	Buy	42,100 +27,100	+181%	+$165K	﹤0.01%	9869
2024 Q4	$122K	Sell	15,000 -3,200	-18%	-$39.6K	﹤0.01%	11160
2024 Q3	$329K	Buy	18,200 +15,700	+628%	+$219K	﹤0.01%	9139
2024 Q2	$25.8K	Sell	2,500 -16,100	-87%	-$166K	﹤0.01%	12414
2024 Q1	$198K	Buy	18,600 +7,500	+68%	+$63.7K	﹤0.01%	10336
2023 Q4	$101K	Sell	11,100 -2,800	-20%	-$24.1K	﹤0.01%	10925
2023 Q3	$144K	Sell	13,900 -25,100	-64%	-$344K	﹤0.01%	10423
2023 Q2	$558K	Sell	39,000 -4,700	-11%	-$54.2K	﹤0.01%	7707
2023 Q1	$312K	Buy	43,700 +36,300	+491%	+$319K	﹤0.01%	9303
2022 Q4	$83K	Sell	7,400 -85,600	-92%	-$882K	﹤0.01%	11471
2022 Q3	$1.03M	Sell	93,000 -3,400	-4%	-$32.4K	﹤0.01%	6918
2022 Q2	$814K	Buy	96,400 +40,000	+71%	+$411K	﹤0.01%	7500
2022 Q1	$768K	Buy	+56,400	New	+$911K	﹤0.01%	8330
2021 Q4	–	Sell	-16,300	Closed	-$523K	–	14498
2021 Q3	$523K	Buy	+16,300	New	+$542K	﹤0.01%	9756